Eli Lilly announces obesity drug retatrutide achieves weight loss results in late-stage trial
Eli Lilly reported that its investigational obesity drug retatrutide met primary and secondary endpoints in a Phase 3 clinical trial, with patients losing up to 28-30% of body weight in the highest dose group. The company administered the drug as a once-weekly injection. This represents a development in the company's pipeline for next-generation obesity treatments.
8
Divergence score
3 outlets covered it, splitting into 3 framing camps across 2 bias groups.
3 camps
2 bias groups
The spectrum · how 3 outlets placed this story
LeftCenterRight
Reuters
The Hill
Wall Street Journal
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Reuters
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Clinical efficacy milestone · positive
Wall Street Journal
Eli Lilly’s New Weight-Loss Treatment Shows Promising Results - WSJ
commercial significance and competitive landscape · positive
First to report
- Wall Street Journalfirst
- Reuters+2.4 h
- The Hill+7.9 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Reuters and The Hill focus on specific weight loss percentages (28-30%), while WSJ emphasizes clinical meaningfulness and market positioning within obesity treatment competition.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 3 outlets
“Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight”
“New obesity drug from Lilly delivers major weight loss”
“Eli Lilly’s New Weight-Loss Treatment Shows Promising Results - WSJ”
5 tracked claims across 3 outlets
Fact ledger
All5Claimed4Corroborated1
1/3
Claimed
Retatrutide met primary endpoint in Phase 3 clinical trial
Corroborated
Disputed
4 more tracked claimsSign up free to see the full ledger